Relpax Patent Fight Revived After Stalled Settlement

Law360, New York (October 4, 2011, 10:15 PM EDT) -- A New York federal judge on Tuesday reopened Pfizer Inc.'s patent infringement suit against Apotex Inc. over the company's plan to sell a generic version of the migraine drug Relpax, after a proposed settlement fell through.

The companies told the court in July that they were close to a settlement, but the settlement “[had] not yet been consummated,” Pfizer said in a notice issued Sept. 7 and signed by U.S. District Judge Lewis A. Kaplan on Tuesday.

Pfizer filed suit in July 2010, after Toronto-based Apotex,...
To view the full article, register now.